Our Gut Microbiome Analysis Technology Platform
We employ an integrated multi-omics platform that combines genomics, proteomics, and metabolomics to assess drug efficacy and elucidate mechanisms of action for gastrointestinal and liver disease therapeutics. Our approach enables systematic analysis of host-microbiome interactions, mucosal immunity, and metabolic reprogramming, delivering actionable insights into disease mechanisms and treatment responses.
Application of Gut Microbiota Analysis in Gastrointestinal Diseases
Ace Therapeutics employs a mature organoid platform to generate human liver organoids that recapitulate both physiological and pathological conditions in vitro.
Ace Therapeutics specializes in preclinical gastroenterology and hepatology research. With expertise in disease model customization, pathology research, drug development, and more, we offer comprehensive solutions to advance scientific discoveries.